Skip to main content Skip to main content
VitalDecades logo VitalDecades
Labs and biomarkers

How often does Medicare pay for an A1C? Twice in 12 months to screen, every three months with diabetes

Brian Keller Healthcare Costs & Consumer Research
11 min read

Who made it and how it was checked

By Brian Keller, Healthcare Costs & Consumer Research. Researched and drafted with AI assistance, then edited by the editor named here. Fact-checked by Sarah Whitcomb, Senior Health Editor, . Its sources are listed on this page. No licensed clinician has reviewed it. How we source.

Report an error on this page

Since January 1, 2024, Medicare counts the A1C as a diabetes screening test: up to two in the 12 months after your most recent screening, if you have a qualifying risk factor. With diabetes, Medicare's national rule treats every three months as enough when it is controlled and allows more when it is not or when treatment changes. High blood pressure or a BMI of 30 or more makes you eligible for screening, but only diabetes, and in our reading prediabetes, moves the A1C to the diagnostic rule. Rules read Nov 16, 2026.

Medicare has paid for the A1C as a diabetes screening test only since January 1, 2024, when the 2024 physician fee schedule rule added it to 42 CFR 410.18. It now covers up to two screening tests in the 12 months after your most recent one, for people with a qualifying risk factor. Once you have diabetes, the A1C moves to a different national rule, NCD 190.21. That rule says testing more often than every three months is not needed when diabetes is controlled. It allows more when diabetes is not controlled or treatment has just changed.

On this page

Which rule applies to your A1C

Codes like Z13.1 are the reason written on the order; five-digit codes like 83036 name the test.

Read November 16, 2026, from 42 CFR 410.18, NCD 190.21 and its October 2026 code list, Medicare.gov and the 2026 lab fee schedule. The last column is what Medicare pays the lab.
Your situationRuleHow often Medicare paysLab rate
No diabetes, at least one risk factor (list below)Screening, 42 CFR 410.18Two tests within 12 months of your most recent screening$9.71 (A1C)
Prediabetes or a past high glucose resultScreening, 42 CFR 410.18; in our reading also billable as diagnostic, since prediabetes is on NCD 190.21's code listTwo screening tests in 12 months; beyond that, expect an advance notice$9.71
Diabetes, stable and at targetDiagnostic, NCD 190.21Not more often than every three months$9.71
Diabetes, treatment just changed, or after major surgery or steroid treatmentDiagnostic, NCD 190.21Every 1 to 2 months "may be appropriate"$9.71
Diabetes not controlledDiagnostic, NCD 190.21More than four times a year, with records showing why$9.71
A1C unreliable (hemolytic anemia or hemoglobinopathies)Diagnostic, NCD 190.21One A1C, then glycated protein (fructosamine) instead$16.76 (fructosamine)

What changed on January 1, 2024

Before 2024, Medicare's diabetes screening benefit paid for glucose tests only: a fasting glucose or a glucose tolerance test, once a year, or twice a year with prediabetes. The calendar year 2024 physician fee schedule rule, published November 16, 2023, finalized three changes: it added the A1C to the covered screening tests, replaced the two frequency limits with the statute's single one, and simplified the definition of diabetes. The regulation now reads: "Medicare covers two tests within the 12-month period following the date of the most recent diabetes screening test of that individual." Medicare.gov puts it as "Up to 2 each year (within 12 months of your most recent screening)."

One CMS document has not caught up. Chapter 18 of the Medicare Claims Processing Manual, in sections last revised in 2005 and 2015, still lists glucose codes only and still describes once every 12 months for people without prediabetes. The regulation is the rule; if a second screening A1C within a year is denied as too frequent, appeal and cite 42 CFR 410.18(c)(3) and (d). CMS's current preventive services chart for providers (October 2026) agrees with the regulation: it lists the A1C among the diabetes screening codes, sets the frequency at "2 screenings within the 12-month period following the date of the patient's most recent diabetes screening test," and adds that people already diagnosed with diabetes "aren't eligible for this benefit." It also notes: "We cover 83036 every 6 months using modifier TS." TS is the "follow-up service" modifier that chapter 18 of CMS's claims manual requires on the extra diabetes screening it allowed for people with prediabetes. Our reading of the two together: space screening A1Cs about six months apart, and the office bills the second with modifier TS. Our type 2 diabetes screening page compares the screening guidelines.

Do you qualify for screening? The risk-factor arithmetic

42 CFR 410.18(e) qualifies you with one of these: high blood pressure; abnormal cholesterol or triglycerides (dyslipidemia); obesity, a BMI of 30 or more; or a past result showing impaired fasting glucose or glucose intolerance. Or with two of these: overweight, which the rule defines as a BMI "greater than 25, but less than 30"; a family history of diabetes; age 65 or older; or gestational diabetes or a baby weighing more than 9 pounds. Age counts as one of the two, which is what the examples below turn on.

Our worked examples from the risk-factor list in 42 CFR 410.18(e).
ExampleQualifies for screening?Why
68, BMI 27, nothing elseYesTwo items from the second list: 65 or older, and overweight
68, BMI 23, a parent with diabetesYes65 or older, and family history
68, BMI 25.0, nothing elseNoA BMI of exactly 25 is not "greater than 25", so age is the only item
58, BMI 31YesObesity qualifies on its own
Any age, on blood pressure medicine for hypertensionYesHigh blood pressure qualifies on its own

Medicare also needs a referral: the screening must follow an order from a physician or qualified nonphysician practitioner for someone "at risk for diabetes." There is no age limit on the screening benefit itself.

Why the reason on the order matters

The national code list for NCD 190.21 (October 2026) includes the screening code Z13.1 "covered only for" the A1C code 83036, and it includes prediabetes (R73.03), impaired fasting glucose (R73.01), impaired glucose tolerance (R73.02), and type 1 and type 2 diabetes, as diagnostic reasons. It does not include high blood pressure (I10), obesity (E66.9), high cholesterol (E78.5) or a family history of diabetes (Z83.3). So a risk factor gets you screened, inside the two-in-12-months limit, but cannot be the reason on a diagnostic A1C. Prediabetes is on the diagnostic list, which in our reading lets a clinician bill a monitoring A1C for prediabetes as diagnostic. Two cautions: the NCD says these tests "are not considered to be medically necessary for the diagnosis of diabetes," and CMS's chart keeps people with prediabetes inside the screening benefit, so a third A1C in 12 months for prediabetes may well be denied. Expect an Advance Beneficiary Notice for it, and ask the office which rule it is billing under.

That NCD sentence, written in 2002, governs the diagnostic rule. The 2024 regulation is what lets an A1C be used to screen.

When an A1C is the wrong test

NCD 190.21 notes that many A1C methods "show significant interference from elevated levels of fetal hemoglobin or by variant hemoglobin molecules," and that glycated protein (fructosamine) testing "is particularly useful in patients who have abnormalities of erythrocytes such as hemolytic anemia or hemoglobinopathies." It allows both tests on the same day once, "limited to the initial assay of glycated hemoglobin, with subsequent exclusive use of glycated protein." Medicare pays $16.76 for fructosamine, $3.93 for a glucose and $12.87 for a three-sample glucose tolerance test. Our guide to what your A1C means covers the conditions that push an A1C falsely high or low.

What triggers a bill

  • A third screening test inside 12 months: denied as more frequent than the benefit allows. A lab can give you an Advance Beneficiary Notice for a frequency limit; if you sign it and go ahead, it can bill its usual fee.
  • A screening A1C with no qualifying risk factor in your record.
  • A diagnostic A1C more often than every three months for controlled diabetes, without records showing why.
  • A third A1C in 12 months for prediabetes: see the cautions above.
  • On Medicare Advantage, diabetes screening tests are preventive services, so 42 CFR 422.100(k) bars cost sharing in network; your plan sets cost sharing for diagnostic tests.

If you are paying cash for an A1C because none of this fits, our A1C price comparison lists four sellers. For what a signed notice commits you to, see our page on the Medicare ABN for lab tests.

Who this may not fit

Pregnancy: NCD 190.21 limits glycated hemoglobin tests to once a month for pregnant women with diabetes, and allows glycated protein monthly. Our guide to what your A1C means lists dialysis, a recent transfusion and hemoglobin variants among the reasons an A1C can mislead; if any applies to you, ask whether fructosamine or a glucose test fits better.

If someone with diabetes is confused, very drowsy or having a seizure, call 911. NIDDK says severe low blood glucose "is dangerous and needs to be treated right away." Nausea and vomiting, fruity-smelling breath or trouble breathing are also reasons to call 911: MedlinePlus lists them as signs of diabetic ketoacidosis. An A1C is never the test for that moment.

What we checked and what we did not

We read 42 CFR 410.18 on eCFR, the CY 2024 physician fee schedule final rule in the Federal Register, NCD 190.21 and its October 2026 code list, chapter 18 of CMS's claims manual, CMS's preventive services chart (MLN006559, October 2026), Medicare.gov's diabetes screening page, the 2026 lab fee schedule, 42 CFR 422.100, and NIDDK's and MedlinePlus's pages for the emergency signs. We did not see how any Medicare contractor's claim system applies the two-test limit, or any Medicare Advantage plan's lab cost sharing.

Every Medicare rate and coverage rule on this page was checked against the pages listed under Sources on November 16, 2026.

Frequently asked questions

How often does Medicare pay for an A1C?

As a screening test, up to two within 12 months of your most recent diabetes screening, if you have a risk factor. With diabetes, NCD 190.21 treats every three months as the norm when it is controlled, and allows more often when it is not or when treatment changes.

Does Medicare cover an A1C for prediabetes?

Yes, as screening, up to two in 12 months. Prediabetes is also on NCD 190.21's diagnostic code list, which in our reading lets a clinician bill a monitoring A1C as diagnostic, but the NCD says these tests are not medically necessary for diagnosing diabetes, so beyond two a year expect an Advance Beneficiary Notice.

Is the A1C covered as diabetes screening?

Yes, since January 1, 2024. Before that, Medicare's screening benefit covered only glucose tests.

What does Medicare pay for an A1C in 2026?

$9.71 to the lab (code 83036), plus $9.34 when a blood draw is billed. You pay nothing for a covered screening when the provider accepts assignment.

I am 65 with a normal weight. Can I get a screening A1C?

Only if something else applies. High blood pressure, abnormal cholesterol, a past high glucose result or a BMI of 30 or more qualifies you on its own. A family history of diabetes, past gestational diabetes, or a BMI over 25 but under 30 qualifies together with your age, which counts as one of two items.

11 sources

These are the sources this guide cites, with each source's date where it publishes one. How we source.

Read next

How often does Medicare pay for a lipid panel? Every 5 years to screen, more often once you are treated

Medicare pays for a screening lipid panel once every 5 years, counted in months: no screening may be paid in the 59 months after the month of your last one. With a covered diagnosis such as high cholesterol, diabetes or high blood pressure, the test is diagnostic instead, and Medicare's national rule allows a yearly panel and, in the first year of treatment, any one part up to six times. A family history of heart disease or smoking, alone, does not count; a relative with familial hypercholesterolemia or high Lp(a) is on the code list, but a reviewer can still treat the test as screening.

Continue reading

Newsletter

One email a week: what changed, what it costs, what to do. Every item sourced and dated.

You're on the list. Look for your first issue next week.

No spam. Unsubscribe anytime.

Was this helpful?

Your feedback shapes what we cover next.

Thanks for letting us know.

If you found this useful, sign up for our newsletter to get more like this.

Thanks. What was missing?

Optional. We read every response.

Thanks.

We use this to prioritize the next round of edits.

Related Articles

More from Brian Keller

More in Labs and biomarkers